



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Licarin A

Cat. No.:	HY-N2252
CAS No.:	51020-86-1
Molecular Formula:	C ₂₀ H ₂₂ O ₄
Molecular Weight:	326.39
Target:	TNF Receptor; Prostaglandin Receptor; COX
Pathway:	Apoptosis; GPCR/G Protein; Immunology/Inflammation
Storage:	4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 50 mg/mL (153.19 mM)
 H₂O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble)
 * "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM	3.0638 mL	15.3191 mL	30.6382 mL
5 mM	0.6128 mL	3.0638 mL	6.1276 mL		
10 mM	0.3064 mL	1.5319 mL	3.0638 mL		

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Licarin A ((+)-Licarin A), a neolignan, significantly and dose-dependently reduces TNF- α production (IC₅₀=12.6 μ M) in dinitrophenyl-human serum albumin (DNP-HSA)-stimulated RBL-2H3 cells. Anti-allergic effects. Licarin A reduces TNF- α and PGD₂ production, and COX-2 expression^[1].

IC₅₀ & Target

DP

In Vitro

Licarin A is found in plants such as Aristolochia taliscana, Machilus thunbergii and Myristica fragrans, which are used as spices and in folk medicines for nervous and digestive disorders. Licarin A also exhibits anti-inflammatory effects^[1]. Licarin A (5-20 μ M) reduces TNF- α and prostaglandin D₂ (PGD₂) secretion via the inhibition of PKC α / β II and p38 MAPK pathways. Licarin A treatment tends to reduce phosphorylated PKC α / β II and p38 MAPK protein levels^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Takuya Matsui, et al. Licarin A Is a Candidate Compound for the Treatment of Immediate Hypersensitivity via Inhibition of Rat Mast Cell Line RBL-2H3 Cells. J Pharm Pharmacol. 2015 Dec;67(12):1723-32.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA